Tang L, Sorajja P, Mooney M, et al. - Researchers sought to determine long‐term results of patients with severe comorbidities (sCM) receiving transcatheter aortic valve replacement (TAVR). This analysis involved all TAVR cases in the Allina Health System (n = 890, 82  ±  8 years, 55% males) between January 1, 2011 and August 7, 2018. The included sCM were: severe lung disease, severe liver disease, end‐stage renal disease, severe, severe dementia, severe dilated cardiomyopathy, and frailty. Comparison was performed between patients with (n = 215, 24%) and without (n = 675, 76%) sCM, in terms of outcomes. At baseline, worse symptoms, higher STS‐PROM and a lower Kansas City Cardiomyopathy Questionnaire score were present in patients with sCM vs those without. A lower 3‐year survival free from all‐cause death, and lower 3‐year survival free from the composite endpoint of all‐cause death, re‐hospitalization for heart failure, myocardial infarction or stroke was observed in patients with sCM vs those without sCM. Overall, poor 3‐year outcomes were observed in TAVR patients with sCM but these patients may exhibit improvements in their quality of life.